Trial Profile

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jul 2026 Results published in the Media Release
05 Dec 2025 According to the Kymera Therapeutics media release, study Led by Professor Jianzhong ZHANG.
05 Dec 2025 According to the Kymera Therapeutics media release, company announced that the new drug application (NDA) for the roconkibart injection for the treatment of adult patients with moderate to severe plaque psoriasis has been accepted by the National Medical Products Administration (NMPA).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com